LumiraDx Receives CE Mark for Two Multiplex Tests: LumiraDx Dual-Target SARS-CoV-2 STAR Complete and LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete

LONDON, June 8, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX) today announced that it has achieved CE Mark for two new Fast Lab Solutions molecular tests, including Dual-Target SARS-CoV-2

Related Keywords

United Kingdom ,London ,City Of ,Sanjay Malkani ,Exchange Commission ,Fast Lab Solutions ,Lumiradx Fast Lab Solutions ,Prnewswire Lumiradx Limited Nasdaq ,Lumiradx Fast Lab ,Lumiradx Platform ,Securities Litigation Reform Act ,Annual Report ,Lumiradx ,Eceives ,Park ,Multiplex ,Tests ,Ual ,Target ,Cars ,Star ,Omplete ,